MarketersMEDIA / Newsroom / First Postpartum Depression Drug Approved by FDA With Instant Relief

First Postpartum Depression Drug Approved by FDA With Instant Relief

Share This Press Release

Brexanolone, is a new fast acting treatment, the first of its kind to be approved by the FDA for Postpartum Depression.

— A New light for moms struggling with postpartum depression has surfaced Tuesday. The Food and Drug Administration has finally approved its first drug aimed directly at treating this condition, called Brexanolone, or Zulresso.

Brexanolone is a miracle because it is a synthetic form of the hormone allopregnanolone, a progesterone derivative, in it. Typically the hormone increases during a women’s pregnancy and then depletes rapidly after the woman gives birth, a primary reason for why most women develop postpartum depression.

“This can potentially transform women’s lives and that of their families,” announced Dr. Steve Kanes, chief medical officer of Sage Therapeutics, the Cambridge, Mass., biopharmaceutical company that developed Brexanolone. “It’s not just the mother who suffers when there’s postpartum depression. It’s the newborn. It’s the other people in their family.”

The medication is not a pill; instead, it is delivered intravenously over the course of 60-hours, which means it would be given in the setting of a hospital or licensed clinic, rather than the patients home.

Clinical studies for the treatment showed terrific results. Not only were the numbers outstanding but the rapid relief that follows the treatment shocked the patients involved.

According to the reports, the team performed a double-blind placebo that included multiple women that experienced moderate to severe postpartum depression. Each woman reported immediate improvements in their symptoms within 24 hours; the improvements were still present after 30 days.

“This is for postpartum depression, but it is a step in understanding how we treat depression more broadly,” explained Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the University of North Carolina at Chapel Hill and the principal academic investigator in the brexanolone trials. “We have had the same treatments for depression for 30 years. There’s an enormous need for new, novel ways to treat depression, and to treat it quickly.”

The treatments approval follows a shocking sign off from the FDA, esketamine, a fast-acting nasal spray that is a form of the popular club drug ketamine, to treat severe depression. The first approval for severe depression treatment since Prozac.
Rapid relief is a focus for many dealing with depression and mental health treatments. The approval for this new treatment is a blessing for many.

A Connecticut mother, who received the treatment, was diagnosed with postpartum depression after she gave birth to her second child, Brenley who is now 2. For years, the antidepressants that she was prescribed were not helping at all, and the patient felt like she was falling deeper and deeper into the state of depression.

Once she participated in the brexanolone trials, she reported incredible results and almost instant relief. She claimed that between hours 12 and 18 of the 60-hour infusion, she noticed her depression slipping away.

“I woke up from a nap, and the thoughts were gone. And they never came back,” Hathaway explained. “And then hour after hour, I got my energy back. I got my appetite back. I was eating because I was hungry, not because people were making me eat.”

However, just like every new drug the treatment is not a cheap price tag, according to Sage it is going to cost the patient anywhere between $20,000 to $35,000 for the infusion. The price does not include the room and board of the hospital or facility, it has not been determined if insurance will cover most of the cost or cover it at all.

The doctors highlight the fact that while the treatment may be pricey, the cost is a one time cost and will change the families lives forever.

“That’s such an important piece as to why this is so novel. We’re talking about a single treatment that has permanent effects,” he said. “This is a one-time intervention that gets people on their way. It’s transformative.”

Dr. Jeff Jonas, CEO of the Massachusetts-based biopharmaceutical company, announced that the drug would be available to the public in June. The medication will only be available through a restricted program, known as the Zulresso Risk Evaluation and Mitigation Strategy (REMS) Program and can be accessed through a doctors recommendation.

If someone is looking for treatment for prescription drug abuse or mental illness close to home, search “Drug Rehab “and use the directory to find a center. For more information, please call our 24-hour hotline, CALL (888) 510-3898

The Recover is an unbiased substance abuse and mental health news provider. Helping individuals looking for the right treatment programs in their area. Also providing information on drug rehab centers for addiction recovery.

Contact: James William
Company: The Recover
Address: Huntington Beach, CA
Contact Number: (888) 510-3898

Contact Info:
Name: James William
Email: Send Email
Organization: The Recover
Address: Huntington Beach, CA
Phone: (888) 510-3898

Source URL:

Source: MarketersMedia

Release ID: 494863

Subscribe and Receive exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2020 MarketersMEDIA – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).